Product Description
Mechanisms of Action: G-CSF
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: New Zealand, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Hepatitis B, Chronic|Intestinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | P2 |
Not yet recruiting |
Intestinal Diseases|Hepatitis B, Chronic |
None |